Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
Yachang Huo(First Affiliated Hospital of Zhengzhou University), Yi Zhang(Tianjin Medical University General Hospital), Wei Lv(Shandong University of Traditional Chinese Medicine), Guohui Qin(Zhengzhou University), Nayoung Han(Seoul National University), Yujie Xu(Henan University), Lihua Liu(Hebei Medical University), Hong Liu(Zhejiang Chinese Medical University), Dan Wang(First Affiliated Hospital of Zhengzhou University), Li Liu(Shihezi University), Lijun Miao(First Affiliated Hospital of Zhengzhou University), Zhixin Zhang(Chengdu University of Technology), Yaqing Liu(Guangzhou University of Chinese Medicine), Hongjie Chen(Shanghai First People's Hospital), Kaiyuan Guo(Allen Institute for Brain Science), Yuqing Duan(Hebei Medical University), Feifei Fan(Peking University), Qingyang Lei(First Affiliated Hospital of Zhengzhou University), Songyun Ouyang(First Affiliated Hospital of Zhengzhou University), Shuangning Yang(First Affiliated Hospital of Zhengzhou University), Liping Wang(Chinese Center For Disease Control and Prevention), Qitai Zhao(First Affiliated Hospital of Zhengzhou University), Chenhui Zhao(First Affiliated Hospital of Zhengzhou University), Shundong Cang(Henan University)
Cited by 22
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis
|The Lancet|2014|3.2k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k